Locoregional radioimmunotherapy in selected patients with malignant glioma: Experiences, side effects and survival times

Journal of Neuro-Oncology

Volumn 62, Issue 3, 2003, Pages 321-328

  Goetz, Claudia ^a   Riva, P ^b   Poepperl, G ^a   Gildehaus, F J ^a   Hischa, A ^a   Tatsch, K ^a   Reulen, H J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b BUFALINI HOSPITAL   (Italy)

Author keywords

Antibody; Glioma; Malignant; Radioimmunotherapy; Tenascin; Therapy

Indexed keywords

ANTIBODY; ANTICONVULSIVE AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; IODINE 131; PHENYTOIN; RADIOPHARMACEUTICAL AGENT; TENASCIN ANTIBODY; UNCLASSIFIED DRUG; YTTRIUM 90;

ACUTE DISEASE; ADULT; AGED; APHASIA; ARTICLE; ASTROCYTOMA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG HALF LIFE; EXPERIENCE; GLIOBLASTOMA; HEADACHE; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; NEUROLOGIC DISEASE; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; SEIZURE; SKIN NECROSIS; SURVIVAL TIME; SYMPTOM; TREATMENT PLANNING; VASCULAR LESION;

ADULT; AGED; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GLIOMA; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TENASCIN; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0038737151     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023309927635     Document Type: Article

References (52)

1. Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E III, Black PM, Coleman CN: Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma. Int J Radiat Oncol Biol Phys 40: 65-70, 1998
2. Madajewicz S, Chowhan N, Tfayli A, Roque C, Meek A, Davis R, Wolf W, Cabahug C, Roche P, Manzione J, Iliya A, Shady M, Hentschel P, Atkins H, Braun A: Therapy for patients with high grad astrocytoma using intraarterial chemotherapy and radiation therapy. Cancer 88: 2350-2356, 2000
3. Davis FG, Freels S, Grutsch J, Barlas S, Brem S: Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: An analysis based on surveillance, epidemiology, and end results (SEER) data, 1973-1991. J Neurosurg 88: 1-10, 1998
4. Bashir R, Hochberg F, Oot R: Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23: 27-30, 1988
5. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ: Imaging-based stereotaxic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66: 865-874, 1987
6. Forsting M, Albert FK, Kunze S, Adams HP, Zenner D, Sartor K: Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. AJNR Am J Neuroradiol 14: 77-87, 1993
7. Wallner KE, Galicich JH, Krol G, Arbit E, Malkin MG: Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16: 1405-1409, 1989
8. Gannett D, Stea B, Lulu B, Adair T, Verdi C, Hamilton A: Stereotactic radiosurgery as an adjunct to surgery and external beam radiotherapy in the treatment of patients with malignant gliomas. Int J Radiat Oncol Biol Phys 33: 461-468, 1995
9. Hudes RS, Corn BW, Werner-Wasik M, Andrews D, Rosenstock J, Thoron L, Downes B, Curran WJ Jr: A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma. Int J Radiat Oncol Biol Phys 43: 293-298, 1999
10. Kondziolka D, Flickinger JC, Bissonette DJ, Bozik M, Lunsford LD: Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms. Neurosurgery 41: 776-783, 1997
11. Alavi JB, Eck SL: Gene therapy for malignant gliomas. Hematol Oncol Clin North Am 12: 617-629, 1998
12. Giese A, Westphal M: Treatment of malignant glioma: A problem beyond the margins of resection. J Cancer Res Clin Oncol 127: 217-225, 2001
13. Sandmair AM, Loimas S, Puranen P, Immonen A, Kossila M, Puranen M, Hurskainen H, Tyynela K, Turunen M, Vanninen R, Lehtolainen P, Paljarvi L, Johansson R, Vapalahti M, Yla-Herttuala S: Thymidine kinase gene therapy for human malignant glioma, using replication-deficient retroviruses or adenoviruses. Hum Gene Ther 11: 2197-2205, 2000
14. Sasaki M, Plate KH: Gene therapy of malignant glioma: Recent advances in experimental and clinical studies. Ann Oncol 9: 1155-1166, 1998
15. Boiardi A, Salmaggi A, Pozzi A, Broggi G, Silvani A: Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: Preliminary data. J Neuro-Oncol 27: 157-162, 1996
16. Bouvier G, Penn RD, Kroin JS, Beique RA, Guerard MJ, Lesage J: Stereotactic administration of intratumoral chronic chemotherapy of recurrent malignant gliomas. Appl Neurophysiol 50: 223-226, 1987
17. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: For the Polymer-Brain Tumor Treatment Group: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345: 1008-1012, 1995
18. Olivi A, Brem H: Interstitial chemotherapy with sustained-release polymer systems for the treatment of malignant gliomas. Recent Results Cancer Res 135: 149-154, 1994
19. Subach BR, Witham TF, Kondziolka D, Lunsford LD, Bozik M, Schiff D: Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: A retrospective case-matched cohort series. Neurosurgery 45: 17-22, 1999
20. Akabani G, Cokgor I, Coleman RE, Gonzalez TD, Wong TZ, Friedman HS, Friedman AH, Garcia-Turner A, Herndon JE, DeLong D, McLendon RE, Zhao XG, Pegram CN, Provenzale JM, Bigner DD, Zalutsky MR: Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46: 947-958, 2000
21. Bigner DD, Brown M, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Bigner SH, Zhao XG, Wikstrand CJ, Pregram CN, Kerby T, Zalutsky MR: Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab′)2 - A preliminary report. J Neuro-Oncol 24: 109-122, 1995
22. Bigner DD, Brown MT, Friedman AH, Coleman RE, Akabani G, Friedman HS, Thorstad WL, McLendon RE, Bigner SH, Zhao XG, Pegram CN, Wikstrand CJ, Herndon JE, Vick NA, Paleologos N, Cokgor I, Provenzale JM, Zalutsky MR: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J Clin Oncol 16: 2202-2212, 1998
23. Brown MT, Coleman RE, Friedman AH, Friedman HS, McLendon RE, Reiman R, Felsberg GJ, Tien RD, Bigner SH, Zalutsky MR, Zhao XG, Wikstrand CJ, Pegram CN, Herndon JE, Vick NA, Paleologos N, Fredericks RK, Schold SC Jr, Bigner DD: Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communications: Phase I trial results. Clin Cancer Res 2: 963-972, 1996
24. Divgi CR, Bander NH, Scott AM, O'Donoghue JA, Sgouros G, Welt S, Finn RD, Morrissey F, Capitelli P, Williams JM, Deland D, Nakhre A, Oosterwijk E, Gulec S, Graham MC, Larson SM, Old LJ: Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clin Cancer Res 4: 2729-2739, 1998
25. Riva P, Arista A, Franceschi G, Frattarelli M, Sturiale C, Riva N, Casi M, Rossitti R: Local treatment of malignant gliomas by direct infusion of specific monoclonal antibodies labeled with 131I: Comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 55: 5952s-5956s, 1995
26. Riva P, Franceschi G, Frattarelli M, Lazzari S, Riva N, Giuliani G, Casi M, Sarti G, Guiducci G, Giorgetti G, Gentile R, Santimaria M, Jermann E, Maeke HR: Loco-regional radioimmunotherapy of high-grade malignant gliomas using specific monoclonal antibodies labeled with 90Y: A phase I study. Clin Cancer Res. 5: 3275s-3280s, 1999
27. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, Zardi L: Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 154: 1345-1352, 1999
28. Kim CH, Bak KH, Kim YS, Kim JM, Ko Y, Oh SJ, Kim KM, Hong EK: Expression of tenascin-C in astrocytic tumors: Its relevance to proliferation and angiogenesis. Surg Oncol 54: 235-240, 2000
29. Vitolo D, Paradiso P, Uccini S, Ruco LP, Baroni CD: Expression of adhesion molecules and extracellular matrix proteins in glioblastomas: Relation to angiogenesis and spread. Histopathology 28: 521-528, 1996
30. Oz B, Karayel FA, Gazio NL, Ozlen F, Balci K: The distribution of extracellular matrix proteins and CD44S expression in human astrocytomas. Pathol Oncol Res 6: 118-124, 2000
31. Bouterfa H, Darlapp AR, Klein E, Pietsch T, Roosen K, Tonn JC: Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neuro-Oncol 44: 23-33, 1999
32. Poepperl G, Goetz C, Gildehaus F-J, Yousry TA, Reulen HJ, Hahn K, Tatsch K: Initial experience with locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV). Neuklearmedizin 41: 120-128, 2002
33. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, Chang CH, Rotman M, Asbell SO, Krisch RE, Nelson DF: Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85: 704-710, 1993
34. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: Who benefits from adjuvant chemotherapy? Ann Neurol 44: 691-695, 1998
35. Prados MD, Levin V: Biology and treatment of malignant glioma. Semin Oncol 27: 1-10, 2000
36. Salminen E, Nuutinen JM, Huhtala S: Multivariate analysis of prognostic factors in 106 patients with malignant glioma. Eur J Cancer 32A: 1918-1923, 1996
37. Black KL, Ciacci JR: The limits of treatment of malignant gliomas. West J Med 158: 65-66, 1993
38. Chamberlain MC, Barba D, Kormanik P, Shea WM: Stereotactic radiosurgery for recurrent gliomas. Cancer 74: 1342-1347, 1994
39. Prados MD, Russo C: Chemotherapy of brain tumors. Semin Surg Oncol 14: 88-95, 1998
40. Schlegel U: Malignant glioma: Who benefits from adjuvant chemotherapy? Ann Neurol 45: 824, 1999
41. Riva P, Franceschi G, Frattarelli M, Riva N, Guiducci G, Cremonini AM, Giuliani G, Casi M, Gentile R, Jekunen AA, Kairemo KJ: 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma - phase I and II study. Acta Oncol 38: 351-359, 1999
42. Riva P, Franceschi G, Riva N, Casi M, Santimaria M, Adamo M: Role of nuclear medicine in the treatment of malignant gliomas: The locoregional radioimmunotherapy approach. Eur J Nucl Med 27: 601-609, 2000
43. Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE, Provenzale JM, Zalutsky MR, Bigner DD: Phase trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. J Clin Oncol 18: 3862-3872, 2000
44. Brady LW, Miyamoto C, Woo DV, Rackover M, Emrich J, Bender H, Dadparvar S, Steplewski Z, Koprowski H, Black P, Lazzaro B, Nair S, McCormack T, Nieves J, Morabito M, Eshleman J: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: A phase II trial. Int J Radiat Oncol Biol Phys 22: 225-230, 1992
45. Hildebrand J, De Witte O, Sahmoud T: Response of recurrent glioblastoma and anaplastic astrocytoma to dibromodulcitol, BCNU and procarbazine - A phase-II study. J Neuro-Oncol 37: 155-160, 1998
46. Murray KJ, Nelson DF, Scott C, Fischbach AJ, Porter A, Farnan N, Curran WJ, Jr: Quality-adjusted survival analysis of malignant glioma. Patients treated with twice-daily radiation (RT) and carmustine: A report of Radiation Therapy Oncology Group (RTOG) 83-02. Int J Radiat Oncol Biol Phys 31: 453-459, 1995
47. Wurschmidt F, Bunemann H, Heilmann HP: Prognostic factors in high-grade malignant glioma. A multivariate analysis of 76 cases with postoperative radiotherapy. Strahlenther Onkol 171: 315-321, 1995
48. Kuzel T, Rosen ST, Zimmer AM, Silverstein EA, Spies S, Saletan SL, Norvitch ME, Birkhofer M, Shochat D, LoBuglio AF, Meredith R, Khazaeli MB, Polansky A, Hu E, Chen D, Lee K, Watkins K: A phase I escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody LYM-1. Cancer Biother 8: 3-16, 1993
49. Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM: Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG. J Nucl Med 38: 858-870, 1997
50. Schold SC Jr, Zalutsky MR, Coleman RE, Glantz MJ, Friedman AH, Jaszczak RJ, Bigner SH, Bigner DD: Distribution and dosimetry of I-123-labeled monoclonal antibody 81C6 in patients with anaplastic glioma. Invest Radiol 28: 488-496, 1993
51. Bruggers CS, Friedman HS, Fuller GN, Tien RD, Marks LB, Halperin EC, Hockenberger B, Oakes WJ, Hoffman JM: Comparison of serial PET and MRI scans in a pediatric patients with a brainstem glioma. Med Pediatr Oncol 21: 301-306, 1993
52. Oppenheimer JH, Levy ML, Sinha U, El Kadi H, Apuzzo ML, Luxton G, Petrovich Z, Zee CS, Miller CA: Radionecrosis secondary to interstitial brachytherapy: Correlation of magnetic resonance imaging and histopathology. Neurosurgery 31: 336-343, 1992